MDM2 antibody | SMP14
MDM2 also acts to stimulate cell proliferation via its induction of transcription factors such as E2F1 and DPI.
MDM2 is over expressed in a range of human malignancies, including soft tissue sarcomas, breast cancer and bladder cancer.
- Target Species
- Species Cross-Reactivity
Target Species Cross Reactivity Mouse
- N.B. Antibody reactivity and working conditions may vary between species.
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide
- Carrier Free
- Synthetic peptide, CSRPSTSSRRRAISE, corresponding to amino acids 154-167 of human MDM2.
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Fusion Partners
- Spleen cells from immunized BALB/c mice were fused with cells of the mouse X63Ag8.653 myeloma cell line.
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- 18 months from date of despatch.
Applications of MDM2 antibody
|Application Name||Verified||Min Dilution||Max Dilution|
|Immunohistology - Frozen|
|Immunohistology - Paraffin 1||1/200||1/500|
|Immunohistology - Resin|
- 1This product requires antigen retrieval using heat treatment prior to staining of paraffin sections. EDTA pH8.0 is recommended for this purpose.
- Histology Positive Control Tissue
- Breast Carcinoma
Secondary Antibodies Available
Product Specific References
References for MDM2 antibody
Picksley, S.M. et al. (1994) Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides.
Oncogene. 9 (9): 2523-9.
Martin, K. et al. (1995) Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein.
Nature. 375 (6533): 691-4.
Gueven, N. et al. (2006) Defective p53 response and apoptosis associated with an ataxia-telangiectasia-like phenotype.
Cancer Res. 66: 2907-12.